NKCL Bio group Inc. (hereinafter referred to as
NKCL Bio Group) is a Korean bio company that researches and develops NK immune
cell treatment using NK immune cell with its competitive technology. Last year,
it had laid the foundation for popularizing NK immune cell treatment by opening
the construction start ceremony of GMP Automated cell cultivation center. In 2020,
it will focus on promoting NKCL’s brand values. As one of its strategies, NKCL
Bio group is signing MOA with various hospitals.
Since signing MOA with the first local
hospital on February 17, NKCL Bio Group continues to engage in work agreements
with local hospitals.
Chairman Shin Dong-Hwa of NKCL Bio Group and Director
Heo Jung of Eden Hospital signed MOA.
NKCL Bio Group’s team are determined to cooperate with Eden hospital team
On March 20th, NKCL Bio Group held
MOA signing ceremony with Eden hospital, Gwang-ju Korea.
Eden hospital is a large-scale hospital with its
medical team of 26 members including Director Heo-Jung, and 150 staffs working.
With its main and new facility in a 5-storied building, Eden Hospital is famous
in Honam region of Korea for its various medical services.
Chairman Shin Dong-Hwa of NKCL Bio group and Director
Heo-Jung of Eden Hospital had a conversation regarding NKCL’s NK immune cell
treatment and shared its direction. Director Heo Jung of Eden hospital has
pointed out that current existing anti-cancer methods impose a great burden on
patient’s body and NK immune cell treatment of NKCL will be the new generation
of anti-cancer treatment without side-effects. He praised on the fact that it
is developed with Korea’s competitive technology.
Chairman Shin Dong-Hwa of NKCL Bio Group and Director
Lim Jung-gu of Delta skin clinic had signed MOA.
NKCL Bio Group’s team are determined to cooperate
with Delta Skin Clinic’s team
Subsequently, on April 2nd, NKCL
Bio Group had signed MOA with Delta skin clinic in Gimpo, Korea. Director Lim Jung-Gu has a master’s degree in
Aerospace medicine and worked as a dermatologist in Seoul National University Hospital.
Using his unique background, Delta skin clinic has implemented Aerospace medicine
to dermatology and created a differentiated concept of a dermatologist specializing
in flight attendants. Since they can treat the skin of flight attendants who are
constantly exposed to a poor condition on the plane, they are confident that
they can also treat the ordinary patients well.
Chairman Shin Dong-Hwa of NKCL Bio Group and Director
Lim Jung-Gu of Delta Skin Clinic shared their vision on NKCL’s NK immune cell
treatment and its expandability and discussed on the areas where both parties
can cooperate to promote synergy.
Chairman Shin Dong-Hwa of NKCL Bio Group had
showed his ambition and said “We are continuously expanding the affiliated
hospitals not only in overseas but also in Korea. In line with the praise of
the company leading the popularization of NK immune cell treatment, we are
planning to establish cooperative hospitals in various parts of Korea.”